febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the 11th annual Advances in Genome Biology and Technology (AGBT) meeting on February 24-27, 2010, in Marco Island , Florida. AGBT is now widely regarded as the premier scientific forum for sharing information about the latest advances in new DNA sequencing technologies and their application to diverse areas in biology and biomedical research. The new HybSelector instrument will replace the Geniom RT Analyzer for highquality DNA enrichment followed by targeted nextgeneration sequencing. The compact HybSelector combines febit's well established expertise in the development and manufacture of technologies for genome exploration with the most advanced highquality DNA enrichment automation available on the market.
"The HybSelector features all technical components necessary for HybSelect, our DNA enrichment protocol," said Peer Staehler, CSO at febit. "We are able to offer the HybSelector at a very competitive price. This will enable the large genomics research community, which has already indicated a high interest in affordable targeted resequencing solutions, to use HybSelect's high sample throughput at low acquisition costs."
The economic benefit of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a limited number of patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort. The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.
"The HybSelector features all technical components necessary for HybSelect, our DNA enrichment protocol," said Peer Staehler, CSO at febit. "We are able to offer the HybSelector at a very competitive price. This will enable the large genomics research community, which has already indicated a high interest in affordable targeted resequencing solutions, to use HybSelect's high sample throughput at low acquisition costs."
The economic benefit of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a limited number of patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort. The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.
